Company intelligence / Profile preview
Nammi Therapeutics
Los Angeles, California, United Statesnammirx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
First patient dosed with QXL138AM in a Phase 1 study evaluating advanced solid tumors and multiple myeloma in November 2024. Preclinical data has demonstrated significant anti-tumor efficacy across more than 10 tumor types, including complete regression in multiple myeloma at doses as low as 0.1 mg/kg.
- Therapeutic areas
- Oncology
- Modalities
- Masked ImmunocytokinesNanocarriers
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Myeloma Investment Fund (MIF)
Beyond the preview
Go deeper on Nammi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nammi Therapeutics.